instruction
stringlengths 33
156
| input
float64 | output
stringlengths 120
1.97k
|
---|---|---|
Does Adalimumab and Acetaminophen interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates. In short, The metabolism of Acetaminophen can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Acetylsalicylic acid interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C9 substrates. In short, The metabolism of Acetylsalicylic acid can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Acyclovir interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates. In short, The metabolism of Acyclovir can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Aducanumab interact? | null | Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Adalimumab is combined with Aducanumab, and the severity of the interaction is minor. |
Does Adalimumab and Agomelatine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates. In short, The metabolism of Agomelatine can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Albendazole interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates. In short, The metabolism of Albendazole can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Aldesleukin interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Aldesleukin is combined with Adalimumab, and the severity of the interaction is major. |
Does Adalimumab and Alectinib interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates with a narrow therapeutic index. In short, The metabolism of Alectinib can be increased when combined with Adalimumab, and the severity of the interaction is major. |
Does Adalimumab and Alemtuzumab interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Adalimumab is combined with Alemtuzumab, and the severity of the interaction is major. |
Does Adalimumab and Alfentanil interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A5 substrates. In short, The metabolism of Alfentanil can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Alirocumab interact? | null | Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Adalimumab is combined with Alirocumab, and the severity of the interaction is minor. |
Does Adalimumab and Allogeneic processed thymus tissue interact? | null | Allogeneic processed thymus tissue for immune reconstitution therapy aims to restore the immune function of patients with severe immunodeficiency caused by congenital athymia. The concomitant use of immunosuppressive agents may interfere with the therapeutic efficacy of immune reconstitution therapy. In short, The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Adalimumab, and the severity of the interaction is minor. |
Does Adalimumab and Almotriptan interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates. In short, The metabolism of Almotriptan can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Alogliptin interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates. In short, The metabolism of Alogliptin can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Alosetron interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates. In short, The metabolism of Alosetron can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Alpelisib interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates with a narrow therapeutic index. In short, The metabolism of Alpelisib can be increased when combined with Adalimumab, and the severity of the interaction is major. |
Does Adalimumab and Alprazolam interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A5 substrates. In short, The metabolism of Alprazolam can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Ambrisentan interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A5 substrates. In short, The metabolism of Ambrisentan can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Aminophylline interact? | null | According to the FDA label for adalimumab 5 the formation of CYP450 enzymes may be suppressed by increased levels of cytokines (for example, TNFα, IL-6) during chronic inflammation. It is possible for a drug that antagonizes cytokine activity, such as adalimumab, to influence the formation of CYP450 enzymes, increasing the metabolism of xanthine derivatives. These drugs are primarily metabolized by CYP450 enzymes. In short, The serum concentration of Aminophylline can be decreased when it is combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Amiodarone interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C8 substrates with a narrow therapeutic index. In short, The metabolism of Amiodarone can be increased when combined with Adalimumab, and the severity of the interaction is major. |
Does Adalimumab and Amitriptyline interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates with a narrow therapeutic index. In short, The metabolism of Amitriptyline can be increased when combined with Adalimumab, and the severity of the interaction is major. |
Does Adalimumab and Amivantamab interact? | null | Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Adalimumab is combined with Amivantamab, and the severity of the interaction is minor. |
Does Adalimumab and Amodiaquine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C8 substrates. In short, The metabolism of Amodiaquine can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Amoxapine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates with a narrow therapeutic index. In short, The metabolism of Amoxapine can be increased when combined with Adalimumab, and the severity of the interaction is major. |
Does Adalimumab and Amphetamine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates. In short, The metabolism of Amphetamine can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Amsacrine interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Adalimumab is combined with Amsacrine, and the severity of the interaction is major. |
Does Adalimumab and Anagrelide interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates with a narrow therapeutic index. In short, The metabolism of Anagrelide can be increased when combined with Adalimumab, and the severity of the interaction is major. |
Does Adalimumab and Anakinra interact? | null | Since adalimumab and abatacept are both immunosuppressants, co-administration of adalimumab and anakinra can increase the risk of infection. In short, The risk or severity of infection can be increased when Adalimumab is combined with Anakinra, and the severity of the interaction is moderate. |
Does Adalimumab and Anastrozole interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C8 substrates. In short, The metabolism of Anastrozole can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Anifrolumab interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Adalimumab is combined with Anifrolumab, and the severity of the interaction is major. |
Does Adalimumab and Ansuvimab interact? | null | Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Adalimumab is combined with Ansuvimab, and the severity of the interaction is minor. |
Does Adalimumab and Anthrax immune globulin human interact? | null | Vaccine efficacy may be reduced when immunosuppressant medications are coadministered. Vaccines are designed to elicit an immune response, and this response may be inhibited by immunosuppressants. The administration of live vaccines can also provide a risk as the infection process can be developed due to the immunosuppressive agent. In short, The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Anthrax vaccine interact? | null | In a placebo-controlled clinical trial of patients with RA, no difference was detected in antipneumococcal antibody response between adalimumab and placebo treatment groups when the pneumococcal polysaccharide vaccine and influenza vaccine were administered concurrently with adalimumab. Similar proportions of patients developed protective levels of anti-influenza antibodies between adalimumab and placebo treatment groups; however, titers in aggregate to influenza antigens were moderately lower in patients receiving adalimumab. In short, The risk or severity of adverse effects can be increased when Adalimumab is combined with Anthrax vaccine, and the severity of the interaction is minor. |
Does Adalimumab and Antilymphocyte immunoglobulin (horse) interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Adalimumab is combined with Antilymphocyte immunoglobulin (horse), and the severity of the interaction is major. |
Does Adalimumab and Antipyrine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates. In short, The metabolism of Antipyrine can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Antithymocyte immunoglobulin (rabbit) interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Adalimumab is combined with Antithymocyte immunoglobulin (rabbit), and the severity of the interaction is major. |
Does Adalimumab and Apalutamide interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C8 substrates. In short, The metabolism of Apalutamide can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Apixaban interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C19 substrates. In short, The metabolism of Apixaban can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Apomorphine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2B6 substrates. In short, The metabolism of Apomorphine can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Apremilast interact? | null | The concomitant administration of apremilast with biologics for rheumatoid arthritis treatment has not been formally evaluated. Several studies have demonstrated that biologic agents frequently used in the treatment of psoriasis or rheumatoid arthritis may impact the metabolism of hepatic cytochrome enzyme substrates (such as apremilast) by stimulating cytochrome enzyme activities. Apremilast is a CYP3A4 substrate, and induction of this enzyme may lead to decreased therapeutic efficacy resulting from increased metabolism. In short, The therapeutic efficacy of Apremilast can be decreased when used in combination with Adalimumab, and the severity of the interaction is major. |
Does Adalimumab and Aprepitant interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A5 substrates. In short, The metabolism of Aprepitant can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Arformoterol interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2A6 substrates. In short, The metabolism of Arformoterol can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Aripiprazole lauroxil interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates. In short, The metabolism of Aripiprazole lauroxil can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Aripiprazole interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates. In short, The metabolism of Aripiprazole can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Arsenic trioxide interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Adalimumab is combined with Arsenic trioxide, and the severity of the interaction is major. |
Does Adalimumab and Asenapine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates. In short, The metabolism of Asenapine can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Asfotase alfa interact? | null | Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Adalimumab is combined with Asfotase alfa, and the severity of the interaction is minor. |
Does Adalimumab and Astemizole interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates with a narrow therapeutic index. In short, The metabolism of Astemizole can be increased when combined with Adalimumab, and the severity of the interaction is major. |
Does Adalimumab and AstraZeneca COVID-19 Vaccine interact? | null | Vaccine efficacy may be reduced when immunosuppressant medications are coadministered. Vaccines are designed to elicit an immune response, and this response may be inhibited by immunosuppressants. The administration of live vaccines can also provide a risk as the infection process can be developed due to the immunosuppressive agent. In short, The therapeutic efficacy of AstraZeneca COVID-19 Vaccine can be decreased when used in combination with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Asunaprevir interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2A6 substrates. In short, The metabolism of Asunaprevir can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Atazanavir interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C9 substrates. In short, The metabolism of Atazanavir can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Atenolol interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates. In short, The metabolism of Atenolol can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Atezolizumab interact? | null | Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Adalimumab is combined with Atezolizumab, and the severity of the interaction is minor. |
Does Adalimumab and Atomoxetine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates. In short, The metabolism of Atomoxetine can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Atorvastatin interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A5 substrates. In short, The metabolism of Atorvastatin can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Avacopan interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Adalimumab is combined with Avacopan, and the severity of the interaction is major. |
Does Adalimumab and Avanafil interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C9 substrates. In short, The metabolism of Avanafil can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Avapritinib interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C9 substrates. In short, The metabolism of Avapritinib can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Avatrombopag interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C9 substrates. In short, The metabolism of Avatrombopag can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Avelumab interact? | null | Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Adalimumab is combined with Avelumab, and the severity of the interaction is minor. |
Does Adalimumab and Axitinib interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates with a narrow therapeutic index. In short, The metabolism of Axitinib can be increased when combined with Adalimumab, and the severity of the interaction is major. |
Does Adalimumab and Azacitidine interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Adalimumab is combined with Azacitidine, and the severity of the interaction is major. |
Does Adalimumab and Azathioprine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates. In short, The metabolism of Azathioprine can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Azelastine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates. In short, The metabolism of Azelastine can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Azithromycin interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates. In short, The metabolism of Azithromycin can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Bacillus calmette-guerin substrain russian BCG-I live antigen interact? | null | VERITY-BCG is a live BCG vaccine used in the treatment of bladder cancer. In order to exert its therapeutic effect, intravesically-administered live BCG vaccines require the development of an immune response - its coadministration with immunosuppressive agents, such as the subject drug, may therefore interfere with anti-tumor efficacy by dampening the desired immune response. In short, The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Adalimumab, and the severity of the interaction is major. |
Does Adalimumab and Bacillus calmette-guerin substrain tice live antigen interact? | null | In a placebo-controlled clinical trial of patients with RA, no difference was detected in antipneumococcal antibody response between adalimumab and placebo treatment groups when the pneumococcal polysaccharide vaccine and influenza vaccine were administered concurrently with adalimumab. Similar proportions of patients developed protective levels of anti-influenza antibodies between adalimumab and placebo treatment groups; however, titers in aggregate to influenza antigens were moderately lower in patients receiving adalimumab. In short, The risk or severity of adverse effects can be increased when Adalimumab is combined with Bacillus calmette-guerin substrain tice live antigen, and the severity of the interaction is minor. |
Does Adalimumab and Bamlanivimab interact? | null | Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Adalimumab is combined with Bamlanivimab, and the severity of the interaction is minor. |
Does Adalimumab and Baricitinib interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Adalimumab is combined with Baricitinib, and the severity of the interaction is major. |
Does Adalimumab and Basiliximab interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Adalimumab is combined with Basiliximab, and the severity of the interaction is major. |
Does Adalimumab and BCG vaccine interact? | null | In a placebo-controlled clinical trial of patients with RA, no difference was detected in antipneumococcal antibody response between adalimumab and placebo treatment groups when the pneumococcal polysaccharide vaccine and influenza vaccine were administered concurrently with adalimumab. Similar proportions of patients developed protective levels of anti-influenza antibodies between adalimumab and placebo treatment groups; however, titers in aggregate to influenza antigens were moderately lower in patients receiving adalimumab. In short, The risk or severity of adverse effects can be increased when Adalimumab is combined with BCG vaccine, and the severity of the interaction is minor. |
Does Adalimumab and Beclomethasone dipropionate interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Adalimumab is combined with Beclomethasone dipropionate, and the severity of the interaction is major. |
Does Adalimumab and Belantamab mafodotin interact? | null | Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Adalimumab is combined with Belantamab mafodotin, and the severity of the interaction is minor. |
Does Adalimumab and Belatacept interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Adalimumab is combined with Belatacept, and the severity of the interaction is major. |
Does Adalimumab and Belimumab interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Adalimumab is combined with Belimumab, and the severity of the interaction is major. |
Does Adalimumab and Belinostat interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Adalimumab is combined with Belinostat, and the severity of the interaction is major. |
Does Adalimumab and Belumosudil interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Adalimumab is combined with Belumosudil, and the severity of the interaction is major. |
Does Adalimumab and Belzutifan interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C19 substrates. In short, The metabolism of Belzutifan can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Bendamustine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates with a narrow therapeutic index. In short, The metabolism of Bendamustine can be increased when combined with Adalimumab, and the severity of the interaction is major. |
Does Adalimumab and Benralizumab interact? | null | Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Adalimumab is combined with Benralizumab, and the severity of the interaction is minor. |
Does Adalimumab and Benzatropine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates. In short, The metabolism of Benzatropine can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Benzocaine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates. In short, The metabolism of Benzocaine can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Benzphetamine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2B6 substrates. In short, The metabolism of Benzphetamine can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Benzyl alcohol interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates. In short, The metabolism of Benzyl alcohol can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Besilesomab interact? | null | Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Adalimumab is combined with Besilesomab, and the severity of the interaction is minor. |
Does Adalimumab and Betamethasone interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Adalimumab is combined with Betamethasone, and the severity of the interaction is major. |
Does Adalimumab and Betaxolol interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates. In short, The metabolism of Betaxolol can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Bevacizumab interact? | null | Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Adalimumab is combined with Bevacizumab, and the severity of the interaction is minor. |
Does Adalimumab and Bexarotene interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C9 substrates. In short, The metabolism of Bexarotene can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Bezlotoxumab interact? | null | Biologic therapies carry a risk of immunogenicity which can produce a wide array of adverse effects the most serious of which include anaphylaxis and serum sickness-type reactions . Use of multiple immunoglobulin-based therapies may increase the risk of these immunological complications. A few studies suggest the use of multiple immunoglobulin agents is relatively safe and may be more effective than monotherapy for certain conditions . In short, The risk or severity of adverse effects can be increased when Adalimumab is combined with Bezlotoxumab, and the severity of the interaction is minor. |
Does Adalimumab and Bicalutamide interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates with a narrow therapeutic index. In short, The metabolism of Bicalutamide can be increased when combined with Adalimumab, and the severity of the interaction is major. |
Does Adalimumab and Bimekizumab interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Adalimumab is combined with Bimekizumab, and the severity of the interaction is major. |
Does Adalimumab and Binimetinib interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates with a narrow therapeutic index. In short, The metabolism of Binimetinib can be increased when combined with Adalimumab, and the severity of the interaction is major. |
Does Adalimumab and Bleomycin interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Adalimumab is combined with Bleomycin, and the severity of the interaction is major. |
Does Adalimumab and Blinatumomab interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Adalimumab is combined with Blinatumomab, and the severity of the interaction is major. |
Does Adalimumab and Bortezomib interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates with a narrow therapeutic index. In short, The metabolism of Bortezomib can be increased when combined with Adalimumab, and the severity of the interaction is major. |
Does Adalimumab and Bosentan interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C9 substrates. In short, The metabolism of Bosentan can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |
Does Adalimumab and Bosutinib interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates with a narrow therapeutic index. In short, The metabolism of Bosutinib can be increased when combined with Adalimumab, and the severity of the interaction is major. |
Does Adalimumab and Brentuximab vedotin interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates with a narrow therapeutic index. In short, The metabolism of Brentuximab vedotin can be increased when combined with Adalimumab, and the severity of the interaction is major. |
Does Adalimumab and Brexpiprazole interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates. In short, The metabolism of Brexpiprazole can be increased when combined with Adalimumab, and the severity of the interaction is moderate. |